Summit Therapeutics, Inc. (SMMT)
17.60
+0.48
(+2.77%)
USD |
NASDAQ |
Sep 04, 16:00
17.59
-0.02
(-0.09%)
Pre-Market: 20:00
Summit Therapeutics SG&A Expense (TTM) : 306.10M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 306.10M |
| March 31, 2026 | 603.76M |
| December 31, 2025 | 556.75M |
| September 30, 2025 | 493.52M |
| June 30, 2025 | 410.79M |
| March 31, 2025 | 64.35M |
| December 31, 2024 | 60.49M |
| September 30, 2024 | 57.69M |
| June 30, 2024 | 42.73M |
| March 31, 2024 | 35.08M |
| December 31, 2023 | 30.29M |
| September 30, 2023 | 26.27M |
| June 30, 2023 | 26.41M |
| March 31, 2023 | 27.02M |
| December 31, 2022 | 26.74M |
| September 30, 2022 | 26.94M |
| June 30, 2022 | 27.03M |
| March 31, 2022 | 26.08M |
| December 31, 2021 | 23.61M |
| September 30, 2021 | 19.67M |
| June 30, 2021 | 20.86M |
| March 31, 2021 | 20.64M |
| December 31, 2020 | 17.13M |
| September 30, 2020 | 13.29M |
| June 30, 2020 | 6.442M |
| Date | Value |
|---|---|
| March 31, 2020 | 0.6682M |
| January 31, 2020 | 0.00 |
| October 31, 2019 | 3.876M |
| July 31, 2019 | 9.916M |
| April 30, 2019 | 13.01M |
| January 31, 2019 | 16.27M |
| October 31, 2018 | 19.27M |
| July 31, 2018 | 15.83M |
| April 30, 2018 | 15.95M |
| January 31, 2018 | 15.72M |
| October 31, 2017 | 12.61M |
| July 31, 2017 | 12.46M |
| April 30, 2017 | 11.91M |
| January 31, 2017 | 10.92M |
| October 31, 2016 | 9.227M |
| July 31, 2016 | 8.781M |
| April 30, 2016 | 7.675M |
| January 31, 2016 | 7.250M |
| October 31, 2015 | 7.196M |
| July 31, 2015 | 5.192M |
| April 30, 2015 | 3.636M |
| January 31, 2015 | 2.015M |
| October 31, 2014 | 0.00 |
| July 31, 2014 | 0.00 |
| April 30, 2014 | 0.00 |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| NovelStem International Corp. | 0.1201M |
| Brainstorm Cell Therapeutics, Inc. | 6.474M |
| Kezar Life Sciences, Inc. | 18.27M |
| Protara Therapeutics, Inc. | 23.56M |
| Clene, Inc. | 7.873M |